STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

GMAB GENMAB A/S StockScouter® Report

4

StockScouter® Score

GENMAB A/S, a mid cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • One or more less experienced analysts has modestly increased quarterly earnings estimates for GMAB. Positive/Neutral
  • Shares are under accumulation by financial institutions. Marginally positive for large companies like GMAB

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 20% done.
Progress: 60% done.
Low
High

Core Model Grades

D
C
D
D

Previous Ratings

3
5
5